Current Trials

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

SPONSOR: vTv Therapeutics
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2). clinicaltrials.gov.

OPEN TO ENROLLMENT

Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease (GAIN Trial)

SPONSOR: Cortexyme Inc.
This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia. clinicaltrials.gov.

OPEN TO ENROLLMENT

A Study of LY3154207 in Participants With Parkinson's Disease Dementia (PRESENCE)

SPONSOR: Eli Lilly
A randomized placebo-controlled trial in individuals with Parkinson's disease dementia to evaluate the safety and efficacy of three doses of study drug LY3154207 in participants with mild-to-moderate Parkinson's disease dementia treated for 12 weeks. clinicaltrials.gov.

OPEN TO ENROLLMENT

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)

SPONSOR: Roche
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose. clinicaltrials.gov.

OPEN TO ENROLLMENT

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease

SPONSOR: Eli Lilly
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD). clinicaltrials.gov.

CLOSED TO ENROLLMENT

Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture)

SPONSOR: Cognito
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment. clinicaltrials.gov

OPEN TO ENROLLMENT